479 related articles for article (PubMed ID: 10350002)
41. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.
Wilkinson GR
J Pharmacokinet Biopharm; 1996 Oct; 24(5):475-90. PubMed ID: 9131486
[TBL] [Abstract][Full Text] [Related]
42. Lack of CYP3A inhibition effects of sertindole on terfenadine in healthy volunteers.
Wong SL; Cao G; Mack R; Granneman GR
Int J Clin Pharmacol Ther; 1998 Mar; 36(3):146-51. PubMed ID: 9562230
[TBL] [Abstract][Full Text] [Related]
43. In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats.
Kageyama M; Namiki H; Fukushima H; Ito Y; Shibata N; Takada K
Biol Pharm Bull; 2005 Feb; 28(2):316-22. PubMed ID: 15684491
[TBL] [Abstract][Full Text] [Related]
44. Induction of human P-glycoprotein in Caco-2 cells: development of a highly sensitive assay system for P-glycoprotein-mediated drug transport.
Shirasaka Y; Kawasaki M; Sakane T; Omatsu H; Moriya Y; Nakamura T; Sakaeda T; Okumura K; Langguth P; Yamashita S
Drug Metab Pharmacokinet; 2006 Oct; 21(5):414-23. PubMed ID: 17072095
[TBL] [Abstract][Full Text] [Related]
45. Transport characteristics of tryptanthrin and its inhibitory effect on P-gp and MRP2 in Caco-2 cells.
Zhu X; Zhang X; Ma G; Yan J; Wang H; Yang Q
J Pharm Pharm Sci; 2011; 14(3):325-35. PubMed ID: 21824448
[TBL] [Abstract][Full Text] [Related]
46. Transport characteristics of ebastine and its metabolites across human intestinal epithelial Caco-2 cell monolayers.
Imamura Y; Shimizu K; Yamashita F; Yamaoka K; Takakura Y; Hashida M
Biol Pharm Bull; 2001 Aug; 24(8):930-4. PubMed ID: 11510488
[TBL] [Abstract][Full Text] [Related]
47. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
48. Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cells.
Bertilsson PM; Olsson P; Magnusson KE
J Pharm Sci; 2001 May; 90(5):638-46. PubMed ID: 11288108
[TBL] [Abstract][Full Text] [Related]
49. Transport proteins and intestinal metabolism: P-glycoprotein and cytochrome P4503A.
Christians U
Ther Drug Monit; 2004 Apr; 26(2):104-6. PubMed ID: 15228147
[TBL] [Abstract][Full Text] [Related]
50. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4.
Katoh M; Nakajima M; Yamazaki H; Yokoi T
Pharm Res; 2000 Oct; 17(10):1189-97. PubMed ID: 11145223
[TBL] [Abstract][Full Text] [Related]
51. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
[TBL] [Abstract][Full Text] [Related]
52. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.
Pauli-Magnus C; von Richter O; Burk O; Ziegler A; Mettang T; Eichelbaum M; Fromm MF
J Pharmacol Exp Ther; 2000 May; 293(2):376-82. PubMed ID: 10773005
[TBL] [Abstract][Full Text] [Related]
53. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.
Lalovic B; Phillips B; Risler LL; Howald W; Shen DD
Drug Metab Dispos; 2004 Apr; 32(4):447-54. PubMed ID: 15039299
[TBL] [Abstract][Full Text] [Related]
54. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
Zhang Y; Guo X; Lin ET; Benet LZ
Drug Metab Dispos; 1998 Apr; 26(4):360-6. PubMed ID: 9531525
[TBL] [Abstract][Full Text] [Related]
55. Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes.
Ling KH; Leeson GA; Burmaster SD; Hook RH; Reith MK; Cheng LK
Drug Metab Dispos; 1995 Jun; 23(6):631-6. PubMed ID: 7587944
[TBL] [Abstract][Full Text] [Related]
56. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
57. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats.
Kalitsky-Szirtes J; Shayeganpour A; Brocks DR; Piquette-Miller M
Drug Metab Dispos; 2004 Jan; 32(1):20-7. PubMed ID: 14709616
[TBL] [Abstract][Full Text] [Related]
58. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD
J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
[TBL] [Abstract][Full Text] [Related]
59. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
Wandel C; Kim RB; Kajiji S; Guengerich P; Wilkinson GR; Wood AJ
Cancer Res; 1999 Aug; 59(16):3944-8. PubMed ID: 10463589
[TBL] [Abstract][Full Text] [Related]
60. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4.
Bhardwaj RK; Glaeser H; Becquemont L; Klotz U; Gupta SK; Fromm MF
J Pharmacol Exp Ther; 2002 Aug; 302(2):645-50. PubMed ID: 12130727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]